Given the significant difference of BCL11A found by integrated analyses, we proposed that BCL11A could be considered as a potential target for ALL treatment and the molecular mechanisms study should be necessary to elucidate the role of BCL11A in MLL-r ALLs. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.